Lyell Immunopharma, Inc. (LYEL)

In the past six months, Lyell Immunopharma, Inc.'s stock price has been impacted by earnings reports, clinical trial progress, financing activities, analyst ratings and insider trading, and overall stock performance. Lyell reported its Q4 and full-year 2025 financial results on March 12, 2026, and its Q1 2026 financial results on May 6, 2026. The company has announced significant progress in its clinical pipeline, including the commencement of patient dosing in the PiNACLE-H2H Phase 3 trial for ronde-cel and continued dosing for LYL273. In March 2026, Lyell closed the second $50 million tranche of a $100 million equity private placement from July 2025, following the achievement of a clinical milestone. Analyst ratings for LYEL have been mixed, ranging from "Strong Buy" to "Sell" recommendations, with an average rating of "Moderate Buy" and an average price target of $43.00 as of May 10, 2026. As of April 22, 2026, the share price was $24.78, representing a significant increase from $9.56 on April 23, 2025.

As a clinical-stage biotechnology company, Lyell Immunopharma, Inc. does not currently have commercialized products, and therefore, direct product or service demand seasonality is not a primary factor influencing its business. However, historical stock data suggests some seasonality in its stock performance, with the stock historically rising by an average of 3.9% over the next 52 weeks based on the past four years.

Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on developing next-generation T-cell therapies for cancer. The company operates in the Healthcare sector, specifically in the Biotechnology industry, focusing on immuno-oncology to enhance the effectiveness and durability of cell-based therapies. Lyell's mission is to advance effective cell therapies for cancer patients by pioneering novel approaches to generate T-cells with potent cancer cell-killing capabilities that drive long-lasting clinical responses. Lyell's major product candidates include Rondecabtagene autoleucel (ronde-cel, also known as LYL314), an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma, and LYL273, an enhanced guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for metastatic colorectal cancer.

Lyell Immunopharma, Inc. is headquartered in South San Francisco, California, and maintains facilities in Seattle and Bothell, Washington.

Lyell Immunopharma's brand reputation in the past year appears mixed but leans towards positive outlooks for its clinical programs, as reflected by analyst sentiment. The company has received an average rating of "Moderate Buy" from analysts. Presentations of strong clinical data for ronde-cel, the acquisition of global rights for LYL273 and its Fast Track designation from the FDA, financial results, and fluctuations in analyst ratings have all affected Lyell Immunopharma's reputation in the past year.

The ownership structure of Lyell Immunopharma (LYEL) is a mix of institutional, insider, and public/individual investors. Approximately 7.24% to 11.22% of the company's stock is owned by institutional investors, while insiders hold about 47.36%. The general public, or individual investors, hold a stake of around 15% to 41.42%. Private equity firms also hold a 20% stake. Major institutional shareholders include Arch Venture Corp, Glaxosmithkline Plc, MWG Caph Ltd, MWG Management Ltd., Vanguard Group Inc, Foresite Capital Management Iv, Llc, Orland Properties Ltd, Almitas Capital LLC, Foresite Capital Management V, LLC, and venBio Partners LLC. Arch Venture Partners, L.P. is noted as a significant shareholder, holding 14% of outstanding shares. Richard Klausner owns the most shares among individual investors.